LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
NCT00412997 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14
Last updated 2012-11-27
Summary
The phase I study will evaluate the safety, efficacy and pharmacokinetics of LBH589B in adult patients with advanced solid tumors or Cutaneous T-cell lymphoma
Conditions
- Tumors
- Cutaneous T-Cell Lymphoma
Interventions
- DRUG
-
LBH589
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-11-30
- Primary Completion
- 2008-05-31
Countries
- Japan
Study Locations
More Related Trials
-
A Study of LY2584702 in Solid Tumors
NCT01241461 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
NCT01238692 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
NCT05828589 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05875428 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
NCT05615974 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
NCT05201248 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
NCT04542824 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
NCT06565689 ·Status: RECRUITING ·Phase: PHASE1
-
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
NCT05206357 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
NCT05365659 ·Status: RECRUITING ·Phase: PHASE1
-
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
NCT05068440 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
NCT01718691 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Localized Low Grade Lymphomas
NCT00536458 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
NCT02955589 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of TQB3820 in Patients With Hematological Malignancies
NCT05020639 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)
NCT02038933 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma
NCT02697552 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma
NCT04827004 ·Status: UNKNOWN ·Phase: PHASE2
-
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
NCT06970496 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
NCT04660799 ·Status: COMPLETED ·Phase: PHASE2
-
Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT05189782 ·Status: UNKNOWN
-
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
NCT07059650 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
NCT05887726 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
NCT03685344 ·Status: TERMINATED ·Phase: PHASE1